Costunolide

Name: Costunolide
Brand: Phytopurify
Rating: 5 (1 reviews)

Catalogue No.： BP0401

CAS NO.: 553-21-9

Purity: 98%

Brand: Phytopurify

Botanical Source: Aucklandia lappa Decne.

Costunolide has antipyretic, anti-inflammatory, anti-oxidant, anti-carcinogenic and anti-fungal activities, it possesses normo-glycemic and hypolipidemic activity. Costunolide inhibits RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity; it inhibits IL-1beta gene expression by blocking the activation of MAPKs and DNA binding of AP-1; it also induces the ROS-mediated mitochondrial permeability transition and resultant cytochrome c release,. Costunolide is a germacranolide with anthelminthic, antiparasitic and antiviral activities. It has a role as a metabolite, an antiinfective agent, an antiparasitic agent, an anthelminthic drug, an antineoplastic agent and an antiviral drug. It is a heterobicyclic compound and a germacranolide.

View larger image

Catalog No	Package	Original Price	Price
BP0401-20mg	20mg	Sign in	Sign in
BP0401-100mg	100mg	Sign in	Sign in
BP0401-1000mg	1000mg	Sign in	Sign in

Contacts：400-829-7929，028-82633860，82633397，82633165

After logging in, view the price and place an order

Consult Collect

Related diseases

Diabetes Mellitus Breast cancer Anti-inflammatory Neurodegenerative disease Osteoarthritis

Related targets

Diabetes Mellitus AMPK NFE2L2 RELA TNF IKBKB NOS2 MAPK8 PPARG PIK3CA PTGS2 NFKB1 CASP3 IL6 IL1B SLC2A4

Breast cancer BCL2 STAT3 AMPK NFE2L2 RELA CASP9 IKBKB MAPK8 PPARG PIK3CA MMP9 EGFR PTGS2 NFKB1 CASP3 HMOX1 BAX CDKN1A

Anti-inflammatory STAT3 RELA TNF IKBKB NOS2 PTGS2 NFKB1 IL6 IL1B

Neurodegenerative disease BCL2 STAT3 AMPK NFE2L2 RELA CASP9 TNF IKBKB NOS2 MAPK8 PPARG PIK3CA EGFR PTGS2 NFKB1 CASP3 IL6 IL1B HMOX1 BAX

Osteoarthritis BCL2 STAT3 AMPK NFE2L2 RELA TNF IKBKB NOS2 MAPK8 PPARG PIK3CA MMP9 PTGS2 NFKB1 CASP3 IL6 IL1B HMOX1 MMP13 ADAMTS5

Product description Related Products Prediction Parameters Reference Literature

Product name: Costunolide
Synonym name:
Catalogue No.: BP0401
Cas No.: 553-21-9
Formula: C₁₅H₂₀O₂
Mol Weight: 232.323
Botanical Source: costus root (Saussurea lappa), Artemisia balchanorum, Talauma ovata, Talauma mexicana, Liriodendron tulipifera, Frullania tamarischii, Frullania nisquallensis, Michelia spp., Magnolia grandiflora, Magnolia sieboldii, Gochnatia foliosa, Chrysa
Physical Description: Cryst.
Type of Compound: Sesquiterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams, up to kilograms.
Inquire for bulk scale.

Descriptions:
Costunolide, a sesquiterpene lactone isolated from the root of Saussurea lappa Clarke, has a variety of biological activities, including anti-carcinogenic and anti-fungal activities,
it inhibits IL-1beta gene expression by blocking the activation of MAPKs and DNA binding of AP-1 in LPS-stimulated RAW 264.7 cells. [1]
Costunolide induces the ROS-mediated mitochondrial permeability transition and resultant cytochrome c release,which is one mechanism of the anticancer effect of costunolide. [2]
Costunolide has antipyretic and anti-inflammatory activities, intraplantar injection of costunolide also reduced the paw oedema, myeloperoxidase. [3]
Costunolide(20mg/kg bw) possesses normo-glycemic and hypolipidemic activity and hence it could be used as a drug for treating diabetes. [4]
Costunolide can reduce the viability and arrest cell cycling at mitosis in hepatoma cells, also enhance the killing effect of radiotherapy against human HCC cells.[5]

References:
[1] Jong Soon Kang, Yeo Dae Yoon, Ki Hoon Lee,et al. Biochem Bioph Res Co, 2004, 313(1):171-177.
[2] Lee M G, Lee K T, Chi S G, et al. Biol Pharm Bull, 2001, 24(3):303-6.
[3] Kassuya C A L, Cremoneze A, Barros L F L, et al. J Ethnopharmacol, 2009, 124(3):369-376.
[4] Eliza J, Daisy P, Ignacimuthu S, et al. J Ethnopharmacol, 2009, 179(2–3):329-334.
[5] Liu C Y, Chang H S, Chen I S, et al. Radiat Oncol, 2011, 6(1):1-8.
[6] Dong S, Liu Y T, Peng J B, et al. Benthamscience Com, 2011, 2(1):74-78.